CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Baricitinib 4 MG Oral TabletWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact

Retrospective study on the efficacy of baricitinib in 12 COVID-19 patients with moderate pneumonia.

NCT04358614 COVID Pneumonia Drug: Baricitinib 4 MG Oral Tablet
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: All adverse event recording

Measure: To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate.

Time: 2 weeks

Secondary Outcomes

Description: The percentage of patients improving the clinical and respiratory parameters compared with controls.

Measure: To evaluate the impact of baricitinib in terms of clinical, laboratory, respiratory parameters.

Time: 2 weeks

Description: The percentage of ICU admission in baricitinib group as compared with controls.

Measure: ICU admission rate

Time: 2 weeks

Description: The percentage of discharged in baricitinib group as compared with controls.

Measure: Discharge rate.

Time: 2 weeks


Related HPO nodes (Using clinical trials)